Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors

Inclusion Criteria: * Male, ≥ 18 years of age * Diagnosis of CD-30 positive germ cell tumor. CD30 expression will be tested by immunohistochemistry (IHC) in archival or fresh tumor tissue as is routinely done for diagnosis. * Disease progression on imaging or tumor marker progression (clinical significance of tumor marker progression to be decided per the discretion of treating physician) after at least 2 lines of platinum-based chemotherapies unless patient is ineligible for further platinum based chemotherapy or refuses 2nd line platinum based chemotherapy due to toxicity. For primary mediastinal germ cell tumors, failure of first-line chemotherapy will be accepted. Prior high dose chemotherapy with hematopoietic stem cell rescue is allowed. Prior treatment with bevacizumab is allowed. * At least 3 weeks should have elapsed since the last treatment (e.g. chemotherapy, targeted small molecule therapy, immunotherapy or radiation) and must have recovered to grade 1 or better from the acute effects of prior therapy. * Presence of measurable disease according to RECIST 1.1 * ECOG performance status 0 or 1 * Adequate marrow and organ function within 28 days prior to study registration as defined below: * Leukocytes \> 3,000/µL * ANC \> 1500/µL * Hemoglobin ≥ 9 g/dL, Note: Blood transfusion will be allowed for patients with hemoglobin \< 9 g/dl and G-CSF is allowed for neutropenic patients at time of enrollment. * Platelets \> 100,000/mm3 * Creatinine: ≤3mg/dl OR if se…